Manufactured by Merck KGaA, Darmstadt, Germany for Provell Pharmaceuticals, LLC
Brand Quality at a Generic Price for all your levothyroxine needs.
Product contains no gluten, lactose, or dyes.
This product contains a boxed warning. Please refer to the full prescribing information, which is linked below.
AB2 rated to Synthroid®
EUTHYROX® (levothyroxine sodium) blister packaging protects the tablets from light and moisture (humidity), either of which can cause any levothyroxine tablet to degrade and lose some of its potency.
Each EUTHYROX® (levothyroxine sodium) tablet is individually sealed. You can rest assured that the strength of the last tablet consumed will be the same as the first.
With EUTHYROX® (levothyroxine sodium) tablets, you can see exactly how many tablets are left before you need to obtain a refill.
Taking your prescription as directed by your healthcare provider every day and having it refilled on-time may result in more consistent thyroid test results.
The outer packaging of EUTHYROX® (levothyroxine sodium) has braille imprinting for the visually impaired.
All strengths of EUTHYROX® (levothyroxine sodium) tablets (25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg and 200 mcg) contain no dyes, lactose or gluten, which may help reduce the potential for adverse effects in patients with sensitivities to those ingredients.
Each scored tablet is embossed with the actual dosage strength (see below).
Tablets shown not actual size. Note the images are illustrative representations of Euthyrox product (e.g., pack size may vary).
DESCRIPTION OF USE
EUTHYROX® (levothyroxine sodium) tablets, is a prescription, thyroid hormone that is used to treat a condition called hypothyroidism. It is meant to replace a hormone that is normally made by your thyroid gland. Generally, thyroid replacement treatment is to be taken for life. EUTHYROX® should not be used to treat noncancerous growths or enlargement of the thyroid in patients with normal iodine levels, or in cases of temporary hypothyroidism caused by inflammation of the thyroid gland (thyroiditis).
IMPORTANT SAFETY INFORMATION
Thyroid hormones, including EUTHYROX®, should not be used either alone or in combination with other drugs for the treatment of obesity or for weight loss. In patients with normal thyroid levels, doses of EUTHYROX® used for daily hormone replacement therapy are not helpful for weight loss. Larger doses beyond what your healthcare provider prescribed may result in serious or even life-threatening events.
•Use EUTHYROX® only as directed by your healthcare provider. •EUTHYROX® is intended to be taken orally as a single dose, preferably on an empty stomach, one-half to one hour before breakfast. •Do not use EUTHYROX® if you have uncorrected adrenal insufficiency. •EUTHYROX® should not be used as a primary or add-on therapy in any weight loss program. •Tell your healthcare provider if you are pregnant or breastfeeding or are thinking of becoming pregnant while taking EUTHYROX®. •Taking too much levothyroxine has been associated with increased bone loss, especially in women after menopause. •Once your healthcare provider has found your specific EUTHYROX® dose, it is important to have lab tests completed, as ordered by your healthcare provider, to ensure that you are on the correct dose. •Talk with your healthcare provider about your diet as foods like soybean flour, cottonseed meal, walnuts, and dietary fiber may cause your body to absorb less EUTHYROX® from the gastrointestinal tract. Grapefruit juice may cause your body to absorb less levothyroxine and may reduce its effect. If you eat these types of food, your dose of EUTHYROX® may need to be adjusted. •Products such as iron and calcium supplements and antacids, can decrease the absorption of levothyroxine; therefore, EUTHYROX® should be taken 4 hours before or after taking these products. •It may take several weeks before you notice an improvement in your symptoms. •Tell your healthcare provider if you are taking any other drugs, including prescription and over-the-counter products. •Tell your healthcare provider about any other medical conditions you may have, especially heart disease, diabetes, blood clotting disorders, and adrenal or pituitary gland problems. The dose of other drugs you may be taking to control these conditions may have to be changed while you are taking EUTHYROX®. If you have diabetes, check your blood sugar levels and/or the glucose in your urine, as ordered by your healthcare provider, and immediately tell your healthcare provider if there are any changes. If you are taking blood thinners, your blood clotting status should be checked frequently. •Tell your healthcare provider or dentist that you are taking EUTHYROX® before any surgery. •Tell your healthcare provider if you develop any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, shaking, change in appetite, weight gain or loss, vomiting, diarrhea, increased sweating, difficulty tolerating heat, fever, changes in menstrual periods, swollen red bumps on the skin (hives) or skin rash, or any other unusual medical event. •Partial hair loss may occur during the first few months you are taking EUTHYROX®.
This is the most important safety information you should know about EUTHYROX®. For more information, talk with your healthcare provider.
Please refer to the full prescribing information located with your EUTHYROX® prescription or visit https://dailymed.nlm.nih.gov
You are encouraged to report negative side effects of prescription drugs to the FDA. You can do this by contacting Provell Pharmaceuticals, LLC at 1-888-899-7041 or by clicking here or contact the FDA at 1 800 FDA 1088 or visit www.fda.gov/medwatch.
References:  Benvenga et al. (2017). Refractory Hypothyroidism Due to Improved Storage of Levothyroxine Tablets. Frontiers in Endocrinology, Vol 8, Article 155.  Data on file – Provell Pharmaceuticals, LLC.  Shrestha et al. (2018) Medication Adherence to Levothyroxine Therapy among Hypothyroid Patients and their Clinical Outcomes with Special Reference to Thyroid Function Parameters. Kathmandu Univ Med J (KUMJ) Apr-Jun; 16(62) 129-137 https://www.ncbi.nlm.nih.gov/pubmed/30636753
Synthroid is a registered trademark of AbbVie Inc.